With the US approval of its combination therapy for glaucoma Rocklatan, Aerie Pharmaceuticals Inc. now has two glaucoma eye-drop products on the market and the firm is agnostic as to which product doctors or patients choose in the early going.
Aerie Looks To Grow Its Two Glaucoma Products In Tandem
The approval of combo therapy Rocklatan gives Aerie two approved glaucoma products; Rhopressa quickly attained wide market access in the US and Aerie expects Rocklatan to fare the same.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
More from Scrip
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.